Clinical Trials | A randomized phase II trial of adjuvant Pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153

The University of Virginia is conducting a clinical research study for adults ages 18 and over with stage I non-small lung cancer that has been completely removed by surgery. The purpose of the study is to find out if giving a drug called pembrolizumab after lung cancer surgery does a better job at keeping the cancer from coming back than surgery alone. The usual approach for patients who are not in a study is to be followed closely by their doctor to watch in case the cancer returns. Participants in this study will be assigned by chance (like a flip of a coin) to be watched closely by their doctor or to receive pembrolizumab. Your participation in this study will be about 1 year. If you complete the study without your disease getting worse, you will be followed for approximately 3 years to check on how you are doing. Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance. Compensation: You will receive a payment of $50 for each study visit you complete. Additional information can be found here: https://clinicaltrials.gov/show/NCT04317534 [email protected]